OKYO Pharma Limited ("OKYO" or the "Company") - Result of Annual General Meeting
OKYO (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on developing novel treatments for inflammatory dry eye diseases and chronic pain, announced that all resolutions were successfully passed at its Annual General Meeting held on September 27, 2021. The details of the proxy voting results will be published on the Company's website. OKYO Pharma is listed on the Official List of the UK Financial Conduct Authority and trades on the main market of the London Stock Exchange.
- All resolutions at the Annual General Meeting were passed unanimously.
- None.
LONDON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- OKYO (LSE: OKYO), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that at the Annual General Meeting, which was held at 10:00 a.m. today, all resolutions were duly passed.
The results of the proxy voting will be available shortly on the Company's website, https://www.okyopharma.com/news.
About OKYO Pharma Limited
OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.
Enquiries:
OKYO Pharma Limited Willy Simon +44 (0)20 7495 2379
For further information, please visit the Company's website at www.okyopharma.com.
FAQ
What significant event occurred for OKYO on September 27, 2021?
What is the ticker symbol for OKYO on OTCQB?
Where can I find the proxy voting results for OKYO's Annual General Meeting?
